Abstracts tagged "pregnancy"

Abstract Number: 0320 • ACR Convergence 2022
Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study
Shi-Nan Luong¹, Isabella Sheldon², Charles Raine³, Elizabeth Jury³ and Ian Giles³, ¹University College London, United Kingdom and University of New South Wales, Sydney, Australia, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by activation of immunological and cellular pathways, disease flares and adverse pregnancy outcomes (APO). Metabolomic…
Abstract Number: 0959 • ACR Convergence 2022
Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data
Amadeia Rector¹, Ivana Marić², Yashaar Chaichian³, Eliza Chakravarty⁴, Miranda Cantu⁵, Michael Weisman⁶, Gary Shaw⁷, Maurice Druzin⁷ and Julia Simard¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University, Stanford, ³Stanford University, Stanford, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Global Lupus Support Group, Portage, MI, ⁶Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Stanford University School of Medicine, Palo Alto
Background/Purpose: Preeclampsia risk is higher among pregnancies in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ), a common first-line treatment, is encouraged in SLE pregnancies…
Abstract Number: 2083 • ACR Convergence 2022
A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy
Massimo Radin¹, Irene Cecchi², Francesca Crisafulli³, Evandro Mendes Klumb⁴, Guilherme Ramires De Jesús⁴, Miguel Ángel Saavedra⁵, Geraldine Vanessa Reyes-Navarro⁶, Luca iaccarino⁷, Maddalena Larosa⁷, Gabriella Moroni⁸, Francesco Tamborini⁹, dario Roccatello¹, Laura Andreoli³, Cecilia Beatrice Chighizola¹⁰ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy, ³University of Brescia, Brescia, Italy, ⁴Instituto Fernandes Figueira, Rio De Janeiro, Brazil, ⁵Hospital de Especialidades Dr. Antonio Fraga Mouret, Ciudad de México, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ⁷University of Padova, Padova, Italy, ⁸Humanitas University, Rozzano, Italy, ⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁰University of Milan, Milano, Italy
Background/Purpose: The complement system is a key-player in the pathogenesis of systemic lupus erythematosus (SLE); decrease in C3 and C4 levels correlates with disease activity…
Abstract Number: 0374 • ACR Convergence 2022
The BASDAI Index During Pregnancy
Olga Krichevskaya, Tatiana Dubinina, Ekaterina Ilinih, Svetlana Glukhova, Anastasia Demina and Irina Andrianova, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: During pregnancy, BASDAI may reflect not only the activity of ankylosing spondylitis (AS), but also back pain and fatigue, that are associated with the…
Abstract Number: 0960 • ACR Convergence 2022
Serum C3 Level and Glucocorticoid Dose Are Risk Factors for Preterm Birth in Patients with Systemic Lupus Erythematosus
Hiromi Shimada¹, Risa Wakiya¹, shusaku nakashima², Mikiya Kato¹, taichi miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Rina Mino⁶, mao mizusaki⁶, Kanako Chujo⁷, Tomohiro Kameda¹ and Hiroaki Dobashi⁸, ¹Kagawa University, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Kagawa University, Kidagun, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁵Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan, ⁸Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan
Background/Purpose: Women with Systemic lupus erythematosus (SLE) have more difficulty in achieving a successful pregnancy than healthy women, because of higher risks for adverse pregnancy…
Abstract Number: 2107 • ACR Convergence 2022
Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension
azalfa Lateef¹, stephanie Bray², Dulaney Wilson², Jim Oates² and Diane Kamen², ¹MUSC, Columbia, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Advances in medicine for women with systemic lupus erythematosus (SLE) have led to improved pregnancy outcomes, but pregnancies are still high-risk and disparities remain.…
Abstract Number: 0941 • ACR Convergence 2022
Surveying Adolescents with Rheumatic Disease for At-Risk Behavior
Kristina Ciaglia¹, Chetna Godiwala², Chan-hee Jo², Tracey Wright³, Lynnette Walters² and Lorien Nassi¹, ¹University of Texas Southwestern, Dallas, TX, ²Scottish Rite Hospital for Children, Dallas, TX, ³UT Southwestern, Plano, TX
Background/Purpose: Adolescents with rheumatic disease are often prescribed teratogenic medications, however few rheumatologists screen patients for sexual activity and provide referrals or contraceptive education due…
Abstract Number: 0961 • ACR Convergence 2022
The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series
Francesca Crisafulli¹, MARIA CHIARA GERARDI², Maria Letizia Urban³, Margherita Zen⁴, Melissa Padovan⁵, Valentina Canti⁶, Emanuela Praino⁷, Cecilia Nalli¹, Francesca Ruffilli⁵, Francesca Saccon⁸, Micaela Fredi⁹, Liala Moschetti¹, Giacomo Emmi³, Luca Iaccarino⁴, Andrea Doria¹⁰, Leonardo Santo⁷, Franco Franceschini¹, Laura Andreoli¹ and Angela Tincani¹¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia and Rheumatology Unit, ASST G.O.M. Niguarda, Milan, Milano, Italy, ³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁴Unit of Rheumatology, Department of Medicine, University of Padova, Padova, Italy, ⁵Rheumatology Unit, Azienda Ospedaliero-Universitaria of Ferrara, Ferrara, Italy, ⁶Division of Immunology, IRCCS San Raffaele Institute, Milano, Italy, ⁷Rheumatology Unit, Presidio Ospedaliero ‘Mons. Dimiccoli’, Barletta, Italy, ⁸Unit of Rheumatology, Department of Medicine, University of Padova and Fondazione Villa Salus, Mestra, Venezia, Italy, ⁹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Manerbio, Italy, ¹⁰Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Via Giustiniani, 2, 35128 Padova, Italy., Padova, Italy, ¹¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy
Background/Purpose: Belimumab (BEL) is an anti-BLyS monoclonal antibody approved for SLE treatment. As few data about BEL use with regard to pregnancy are available, the…
Abstract Number: 2191 • ACR Convergence 2022
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
In Ah Choi¹, Ji Hyoun Kim², Sung Hae Chang³, Hyun Jung Kim⁴ and Hyeong Sik Ahn⁴, ¹Chungbuk National University, Cheongju, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ⁴Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
Abstract Number: 0945 • ACR Convergence 2022
Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry
John Bridges¹, Jing Li², Melissa Mannion³, Gabriela Schmajuk⁴ and Jasvinder singh³, ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of California, San Francisco, San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients with juvenile idiopathic arthritis (JIA) have disease onset during childhood and often require anti-rheumatic medication through their reproductive years. Contraception use in reproductive-age…
Abstract Number: 0962 • ACR Convergence 2022
Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
Megan Clowse¹, Jim Oates², Katie Kirchoff², April Barnado³, Saira Sheikh⁴, Leslie Crofford³ and Amanda Eudy⁵, ¹Duke University, Durham, NC, ²Medical University of South Carolina, Charleston, SC, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Disparities in pregnancy outcomes among women with SLE remain understudied, with few available racially-diverse datasets. We previously validated algorithms to identify pregnancies in women…
Abstract Number: 2192 • ACR Convergence 2022
Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability
Leah K. Flatman¹, Yvan St. Pierre², Isabelle Malhamé³, Olga Basso¹, Anick Berard⁴, Sasha Bernatsky² and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴University of Montreal, Montréal, QC, Canada
Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the…
Abstract Number: 0023 • ACR Convergence 2021
Investigating Temporal Changes in Pregnancy Among Women with Rheumatoid Arthritis and Healthy Women Using Co-expression Network Analysis
Matthew Wright¹, Dana Goin², Mette Smed³, J Lee Nelson⁴, Nicholas Jewell⁵, Jorn Olsen⁶, Merete Hetland⁷, Vibeke Zoffmann³ and Damini Jawaheer⁸, ¹UCSF Benioff Children's Hospital Oakland, Oakland, CA, ²University of California San Francisco, San Francisco, CA, ³Juliane Marie Center, Rigshospitalet, Copenhagen, Denmark, ⁴Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, ⁵University of California Berkeley, Berkeley, CA, ⁶Aarhus University Hospital, Aarhus, Denmark, ⁷DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁸UCSF Benioff Children's Hospital Oakland / University of California San Francisco, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA), while still an incurable disease, can often improve naturally during pregnancy. The specific mechanism(s) underlying this pregnancy-induced improvement, however, are not…
Abstract Number: 1717 • ACR Convergence 2021
One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center
Yixuan Zhou¹ and Sobia Hassan², ¹Rush University Medical Center, Chicago, IL, ²RUSH University, Chicago, IL
Background/Purpose: Successful pregnancies in patients with rheumatic disease are possible when they are well-monitored, adequately treated, and planned during periods of disease quiescence. Previously, a…
Abstract Number: 0070 • ACR Convergence 2021
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Ecem Sevim², Guilherme Ramires de Jesus³, Ricard Cervera⁴, Lanlan Ji⁵, Vittorio Pengo⁶, Amaia Ugarte⁷, Danieli Andrade⁸, Laura Andreoli⁹, Tatsuya Atsumi¹⁰, Paul R Fortin¹¹, Maria Gerosa¹², Yu Zuo¹³, Michelle Petri¹⁴, Savino Sciascia¹⁵, Maria Tektonidou¹⁶, Maria Angeles Aguirre¹⁷, D. Ware Branch¹⁸, Doruk Erkan¹ and on Behalf of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Montefiore Medical Center - Wakefield Campus, Bronx, NY, ³Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Peking University First Hospital, Beijing, China (People's Republic), ⁶Padova University Hospital, Padova, Italy, ⁷Hospital Universitario Cruces, Barakaldo, Spain, ⁸Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹University of Brescia, Brescia, Italy, ¹⁰Hokkaido University, Sapporo, Japan, ¹¹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹²University of Milan, Milan, Italy, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵University of Turin, Turin, Italy, ¹⁶FORZAFORTE HELLAS LTD, Athens, Greece, ¹⁷IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹⁸University of Utah, Salt Lake City, UT
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].